Antioxidant effects of resveratrol in granulocytes from multiple sclerosis patients

• Published in: Exploration of neuroscience Vol. 3; no. 5; pp. 362 - 374
• Main Authors: Pedro Henrique Villar-Delfino, Regiane Penaforte Santos, Paulo Pereira Christo, José Augusto Nogueira-Machado, Caroline Maria Oliveira Volpe
• Format: Journal Article
• Language: English
• Published: Open Exploration Publishing Inc 03-09-2024
• Subjects: cytokine; inflammation; innate immunity; multiple sclerosis; reactive oxygen species; resveratrol
• ISSN: 2834-5347
• DOI: 10.37349/en.2024.00055

Aim: Neuroinflammation is a characteristic of multiple sclerosis (MS). Resveratrol (RSV) has potent antioxidant properties and has emerged as a promising therapeutic agent for various inflammatory diseases. This study investigated the effects of RSV on inflammatory responses via reactive oxygen species (ROS) production and leukocyte cytokine secretion in patients with MS and healthy controls. Methods: The effects of RSV on ROS production in resting and stimulated granulocytes (in the presence of opsonized particles) were assessed using luminol-dependent chemiluminescence. The cytokines interleukin (IL)-10, IL-1β, IL-6, and high mobility group box 1 (HMGB1) in the supernatant of peripheral blood mononuclear cells (PBMNCs) were quantified using enzyme-linked immunosorbent assay (ELISA). Results: RSV significantly downregulated ROS production in resting and stimulated granulocytes in patients with MS and healthy controls. In the control group, RSV reduced IL-6 levels by 49% in the PBMNC supernatant, whereas IL-6 levels remained unchanged in the MS group. Interestingly, higher levels of IL-10 were detected in PBMNC supernatants from patients with MS than in controls. No significant changes were observed in IL-1β and HMGB1 levels in the PBMNC supernatant. Conclusions: Controlling ROS production is a key target for treating inflammatory diseases. Our findings suggest that RSV can effectively modulate ROS production in MS, highlighting its potential as a promising adjunct therapy for controlling oxidative innate immune responses in MS.